Using genetic markers to orient the edges in quantitative trait networks: the neo software



Yüklə 492 b.
tarix23.11.2017
ölçüsü492 b.
#12186



Using genetic markers to orient the edges in quantitative trait networks: the NEO software.

  • Using genetic markers to orient the edges in quantitative trait networks: the NEO software.

    • Aten JE, Fuller TF, Lusis AJ, et al (2008) BMC Systems Biology 2008, 2:34. April 15.
    • Chapter 11 in Springer book “Weighted Network Analysis. Applications in Genomics and Systems Biology”
  • Application

    • Plaisier et al (2009) A Systems Genetics Approach Implicates USF1, FADS3, and Other Causal Candidate Genes for Familial Combined Hyperlipidemia. PloS Genetics 2009;5(9)




Question: Can genetic markers help us to dissect causal relationships between gene expression- and clinical traits?

  • Question: Can genetic markers help us to dissect causal relationships between gene expression- and clinical traits?

  • Answer: yes, many authors have addressed this question both in genetics and in genetic epidemiology.

    • Vast literature->google search


Sequence variation->gene expression (messenger RNA)->protein->clinical traits

  • Sequence variation->gene expression (messenger RNA)->protein->clinical traits

  • SNPs are “causal anchors”

  • SNP -> gene expression

    • Schadt et al 2005.






Input Data

  • Input Data

  • A set of quantitative variables (traits)

    • e.g. many physiological traits, blood measurements, gene expression data
  • SNP marker data (or genotype data)

  • Output

  • Scores for assessing the causal relationship between correlated quantitative variables





LEO - compares local structural equation models; the more positive the score, the stronger the evidence

  • LEO - compares local structural equation models; the more positive the score, the stronger the evidence















FCHL is a common atherogenic dyslipidemia conferring nearly two-fold greater risk for coronary heart disease.

  • FCHL is a common atherogenic dyslipidemia conferring nearly two-fold greater risk for coronary heart disease.

  • FCHL is characterized by familial segregation of elevated fasting plasma triglycerides (TGs), total cholesterol (TC), or both

  • Another common characteristic of FCHL is elevated levels of fasting plasma apolipoprotein B (ApoB)



Linkage analysis and allelic association studies identified association within the region of chromosome 1q21-q23 consistently linked to FCHL with the associated linkage disequilibrium (LD) bin containing variants in upstream transcription factor 1 (USF1)

  • Linkage analysis and allelic association studies identified association within the region of chromosome 1q21-q23 consistently linked to FCHL with the associated linkage disequilibrium (LD) bin containing variants in upstream transcription factor 1 (USF1)

  • A SNP (SNP rs3737787 residing in the 3′ UTR of USF1 captures the disease-associated signal

  • Previous studies involving direct sequencing, extensive genotyping and gene expression analyses of the USF1 region have not identified any SNPs in the rs3737787 LD bin altering the coding sequence or the expression of USF1 itself in fat or lymphoblasts

  • It has, however, been demonstrated that genes known to be regulated by USF1 were differentially expressed between rs3737787 genotype groups in Finnish fat biopsies.

  • The direct targets of USF1 were previously identified using chromatin immunoprecipitation and high-resolution promoter microarrays (ChIP-Chip).



  • Originally, 872 individuals from 74 Mexican FCHL families were collected.

  • 70 extremely discordant individuals

    • The 90th age-sex specific Mexican population percentiles for TGs and TC were used to determine the affection status
  • Gene expression data: Affymetrix U133Plus2

  • Our sample size of 70 extremely discordant individuals provided 80% power to detect a significant association (p-value≤0.05) with correlation coefficient = 0.33



We observed 972 genes (gene expression profiles) significantly correlated with rs3737787 genotypes using an additive model.

  • We observed 972 genes (gene expression profiles) significantly correlated with rs3737787 genotypes using an additive model.

  • The rs3737787 correlated genes had significant overlap both with

    • i) the set of USF1 regulated genes identified in our USF1 over-expression experiment (n = 277; p-value = 3.0×10−5; fold-enrichment = 1.22)
    • and ii) the previously published genes identified by ChIP-Chip which are directly regulated by USF1 (n = 117; p-value = 0.0051; fold-enrichment = 1.23).
    • Furthermore, we also observed significant overlap between the rs3737787 correlated genes and the 2,189 genes differentially expressed between FCHL cases and normolipidemic controls (n = 245; p-value = 0.0030; fold-enrichment = 1.16) supporting a link from rs3737787 to FCHL etiology.
  • Taken together, the overlap between rs3737787 correlated genes and genes regulated by USF1 suggest that the effect of rs3737787 on FCHL is mediated through the transcription factor USF1.



Using blockwise module detection, WGCNA method clustered the 14,942 gene expression probes on the Mexican FCHL case/control microarrays into 28 gene co-expression modules.

  • Using blockwise module detection, WGCNA method clustered the 14,942 gene expression probes on the Mexican FCHL case/control microarrays into 28 gene co-expression modules.

  • The module eigengene (ME) of each module was correlated with the quantitative FCHL component traits: TC, TG and ApoB.

  • Regarding Bonferroni correction: Given the high level of correlation between the FCHL component traits (correlation TC & TG = 0.57; correlation TC & ApoB = 0.90; correlation TG & ApoB = 0.59), we approximate the total number of independent tests to be 2. Therefore, a Bonferroni correction would have to account for a total of 56 multiple comparisons (28 modules×2 independent tests).

  • This highlights a major statistical advantage of our module based analyses over conventional differential expression analyses which have to account for tens of thousands of multiple comparisons.





Tan module (504 genes) was renamed URFA module

  • Tan module (504 genes) was renamed URFA module

  • The fact that the URFA ME was associated with rs3737787 reflects the fact that most module genes are at least partially regulated by this SNP

  • Gene ontology enrichment

    • Cellular Lipid Metabolic Processes (p-values = 1.0×10−5) and Lipid Metabolic Processes (9.3×10−6)
  • The URFA ME accounts for 10% of the variation of FCHL, 6% of TC, 17% of TG, and 9% of ApoB



To evaluate whether the module causally affects FCHL component traits, we utilized the Network Edge Orienting (NEO) R software package

  • To evaluate whether the module causally affects FCHL component traits, we utilized the Network Edge Orienting (NEO) R software package

  • Since we are only considering a single SNP (rs3737787) we computed LEO.NB.SingleMarker scores for the causal orientation of a ME→trait.

  • The LEO.NB.SingleMarker score is a relative model fitting index for the causal model rs3737787→ME→trait relative to alternative causal models

  • We required that the causal model fit at least two times better than the next best alternative model, which equates to a LEO.NB.SingleMarker score of 0.3



We found sufficient evidence to infer a causal relationship between the URFA ME and fasting plasma TG levels (LEO.NB.SingleMarker score = 0.31), the key component trait of FCHL.

  • We found sufficient evidence to infer a causal relationship between the URFA ME and fasting plasma TG levels (LEO.NB.SingleMarker score = 0.31), the key component trait of FCHL.

  • The LEO.NB.SingleMarker score for the URFA ME to FCHL was 0.25.



We then used the NEO software to prioritize genes inside the URFA module by calculating the LEO.NB.SingleMarker scores evaluating the causal model (rs3737787→gene expression→trait).

  • We then used the NEO software to prioritize genes inside the URFA module by calculating the LEO.NB.SingleMarker scores evaluating the causal model (rs3737787→gene expression→trait).

  • We identified

  • Since our interest was in FCHL disease status, we characterized the 18 causal candidate genes for FCHL disease status as potential candidate genes for genetic association studies in Mexican FCHL families





Three of the FCHL causal candidate genes were directly related to lipid phenotypes (ABCC6, AKT2, HSD11B1), and two others were likely to be related to lipid phenotypes (FADS3, PNPLA4) via homology.

  • Three of the FCHL causal candidate genes were directly related to lipid phenotypes (ABCC6, AKT2, HSD11B1), and two others were likely to be related to lipid phenotypes (FADS3, PNPLA4) via homology.

  • We also identified genes which were related to atherogenic processes such as inflammation (CARD8, ICSBP1, STX6) and reactive oxygen species (GCLM).

  • Importantly, some of the genes causally linked to FCHL (ABCC6, AKT2, FADS3, GCLM, HSD11B1) have already been associated with FCHL related traits in humans. Studies in mice have also demonstrated that genetic manipulation of Abcc6, Akt2 and Hsd11b1 affect FCHL component traits or related phenotypes.

  • Together these data support a causal association between the 18 causal candidate genes from the URFA module and FCHL.

  • Among the 18 genes there are also putative genes and genes with little known function.

  • Additional biological validation studies are warranted



Interestingly, variation from the FADS1-2-3 genomic region was previously associated with TGs in a recent meta-analysis of GWAS in Caucasians.

  • Interestingly, variation from the FADS1-2-3 genomic region was previously associated with TGs in a recent meta-analysis of GWAS in Caucasians.

  • We chose to follow-up the SNP rs174547 residing in the FADS1-2-3 locus which was significantly associated with TGs at the genome-wide level in this previous meta-analysis.

  • The same study demonstrated that the SNP rs102275, in complete LD with rs174547 in Caucasians, predicted the expression of FADS1 and to a lesser extent FADS3 in human liver (Kathiresan 2009).

  • We hypothesized that because FADS3 expression was associated with FCHL, any variation affecting the expression of FADS3 could be associated with FCHL or an FCHL component trait, especially TGs.

  • Therefore we genotyped both rs174547 and rs102275 in the Mexican FCHL case/control fat biopsies (n = 70). Our results replicated the findings for the FADS1-2-3 locus in the Mexican population.



First, co-expression modules may be comprised of sets of genes that are likely to be co-regulated by similar factors (e.g. shared transcription factors, genetic variants or environmental effects).

  • First, co-expression modules may be comprised of sets of genes that are likely to be co-regulated by similar factors (e.g. shared transcription factors, genetic variants or environmental effects).

  • Second, modules (and corresponding module eigengenes) represent a biologically motivated data reduction method which greatly alleviates the multiple comparison problem inherent in genomic data analysis.

  • Third, kME (intramodular connectivity) can be used to provide annotation tables for module membership e.g. to the URFA module



  • By integrating a genetic polymorphism with genome-wide gene expression levels, we were able to attribute function to a genetic polymorphism in the USF1 gene.

  • We demonstrate that this genetic polymorphism in USF1 contributes to FCHL disease risk by modulating the expression of a group of genes functionally related to lipid metabolism, and that this modulation is mediated by USF1.

  • Our unbiased module detection analysis identified a module (the URFA module) that was associated with rs3737787 genotypes, fasting plasma TG levels, FCHL disease status, and contained genes that are causal drivers of TG levels.

  • Our approach provides insight to how the SNP rs3737787 confers increased risk for FCHL, by demonstrating that it regulates the URFA module eigengene which in turn contributes to increased TG levels, a key component trait of FCHL.

  • One of the genes whose expression is modulated by USF1 is FADS3, which was also implicated in a recent genome-wide association study for lipid traits.

  • We demonstrated that a genetic polymorphism from the FADS3 region, which was associated with triglycerides in a GWAS study of Caucasians, was also associated with triglycerides in Mexican FCHL families.

  • Our analysis provides novel insight into the gene expression profile contributing to FCHL disease risk, and identifies FADS3 as a new gene for FCHL in Mexicans.



For R code see “Corrected Tutorial for Chapter 12” at the following webpage:

  • For R code see “Corrected Tutorial for Chapter 12” at the following webpage:

    • http://www.genetics.ucla.edu/labs/horvath/CoexpressionNetwork/Book/
  • Or the original NEO webpage:

  • www.genetics.ucla.edu/labs/horvath/aten/NEO/



(Former) students and Postdocs:

  • (Former) students and Postdocs:

  • Peter Langfelder, Jun Dong, Tova Fuller, Mike Oldham, Ai Li, Wen Lin, Jeremy Miller, Chris Plaisier, Anja Presson, Bin Zhang, Wei Zhao, Jason Aten, Lin Song

  • Colleagues/Collaborators

  • Jake Lusis, Paivi Pajukante,

  • Dan Geschwind, Giovanni Coppola



Yüklə 492 b.

Dostları ilə paylaş:




Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©genderi.org 2024
rəhbərliyinə müraciət

    Ana səhifə